In one of JP Mor­gan's first biotech bets, En­laza rais­es $100M for its per­ma­nent­ly bind­ing pro­tein drugs

En­laza Ther­a­peu­tics raised $100 mil­lion to de­vel­op per­ma­nent­ly bind­ing an­ti­body-drug con­ju­gates for can­cer with a goal of bring­ing them in­to the first-ever hu­man stud­ies.

The com­pa­ny an­nounced Tues­day that the Se­ries A round was led by JP Mor­gan’s Life Sci­ences Pri­vate Cap­i­tal, which was formed in late 2022 to in­vest in ear­ly-stage biotech com­pa­nies. En­laza is the firm’s first dis­closed in­vest­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER